Drug interaction between standardized herbal medicines by the Unified Health System and conventional medicines

Detalhes bibliográficos
Autor(a) principal: Rubio, Karina Taciana Santos
Data de Publicação: 2022
Outros Autores: Nascimento, Maria Alice Pereira do, Martucci, Maria Elvira Poleti
Tipo de documento: Artigo
Idioma: por
Título da fonte: Revista Fitos
Texto Completo: https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/1138
Resumo: Medicinal plants and phytotherapics are considered an alternative for the treatment of several diseases. The SUS has 12 phytotherapics standardized in the RENAME: artichoke, mastic, aloe vera, holy cashew, espinheira-santa, devil's claw, guaco, mint, soy isoflavone, plantago, willow and unha-de-gato. The aim of this work was to evaluate the adverse events of these phytotherapics and the possible drug interactions resulting from the use of conventional medicines concomitant with the use of these phytotherapics. The work was carried out through a review of the databases between 1995 and 2020. Medicinal plants and phytotherapics are constituted of chemical compounds, which are mostly responsible for their pharmacological actions. The complexity of these substances increases the possibility of interactions occurring when conventional drugs are used concomitantly. The interactions can be beneficial or unfavorable, since they can increase drug's effect, reduce its effectiveness, result in adverse reactions or not cause changes in the expected effect of the drug. This work emphasizes the importance of considering herbal medicines and phytotherapics with the same importance as synthetic medicines, basing clinical conduct on reliable scientific evidence, recognizing its effectiveness, but also its adverse effects and the possibility of drug interactions making, thus, its use safer and more efficient.
id FIOCRUZ-1_9c98670aeab89d5e8d71ed8bb61c2e60
oai_identifier_str oai:ojs.revistafitos.far.fiocruz.br:article/1138
network_acronym_str FIOCRUZ-1
network_name_str Revista Fitos
repository_id_str
spelling Drug interaction between standardized herbal medicines by the Unified Health System and conventional medicinesInterações medicamentosas entre fitoterápicos padronizados pelo Sistema Único de Saúde e medicamentos convencionaisPhytotherapicsPhytotherapyAdverse eventsDrug interactionsMedicinal plantsUnified Health SystemFitoterápicosFitoterapiaEventos adversosInterações medicamentosasPlantas MedicinaisSistema Único de SaúdeMedicinal plants and phytotherapics are considered an alternative for the treatment of several diseases. The SUS has 12 phytotherapics standardized in the RENAME: artichoke, mastic, aloe vera, holy cashew, espinheira-santa, devil's claw, guaco, mint, soy isoflavone, plantago, willow and unha-de-gato. The aim of this work was to evaluate the adverse events of these phytotherapics and the possible drug interactions resulting from the use of conventional medicines concomitant with the use of these phytotherapics. The work was carried out through a review of the databases between 1995 and 2020. Medicinal plants and phytotherapics are constituted of chemical compounds, which are mostly responsible for their pharmacological actions. The complexity of these substances increases the possibility of interactions occurring when conventional drugs are used concomitantly. The interactions can be beneficial or unfavorable, since they can increase drug's effect, reduce its effectiveness, result in adverse reactions or not cause changes in the expected effect of the drug. This work emphasizes the importance of considering herbal medicines and phytotherapics with the same importance as synthetic medicines, basing clinical conduct on reliable scientific evidence, recognizing its effectiveness, but also its adverse effects and the possibility of drug interactions making, thus, its use safer and more efficient.As plantas medicinais e os fitoterápicos são alternativas para o tratamento de diversas doenças. O Sistema Único de Saúde (SUS) possui 12 fitoterápicos padronizados na Relação Nacional de Medicamentos Essenciais (RENAME): alcachofra, aroeira, babosa, cáscara-sagrada, espinheira-santa, garra-do-diabo, guaco, hortelã, isoflavona-de-soja, plantago, salgueiro e unha-de-gato. O objetivo deste trabalho foi avaliar os eventos adversos destes fitoterápicos e as possíveis interações medicamentosas resultantes do seu uso concomitante com medicamentos convencionais. O trabalho foi realizado por meio de uma revisão narrativa da literatura no período entre 1995 e 2020. As plantas medicinais e/ou os medicamentos fitoterápicos são constituídos de compostos químicos, que em sua maioria são responsáveis pelas suas variadas ações farmacológicas. A composição química complexa aumenta a possibilidade de interações quando medicamentos convencionais são utilizados concomitantemente. As interações podem ser benéficas ou desfavoráveis, podendo potencializar o efeito de fármacos, reduzir a eficácia, resultar em reações adversas ou não alterar o efeito esperado do fármaco. Ressaltou-se a importância de considerar os fitoterápicos/plantas medicinais com a mesma importância que os medicamentos sintéticos, baseando a conduta clínica em evidências científicas confiáveis, reconhecendo sua eficácia, mas também seus efeitos adversos e a possibilidade de interações medicamentosas tornando, assim, seu uso mais seguro e eficaz.Centro de Inovação em Biodiversidade e Saúde - Farmanguinhos/Fiocruz2022-06-30info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdftext/htmltext/xmlhttps://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/113810.32712/2446-4775.2022.1138Revista Fitos; Vol. 16 No. 2 (2022); 248-269Revista Fitos; Vol. 16 Núm. 2 (2022); 248-269Revista Fitos; v. 16 n. 2 (2022); 248-2692446-47751808-9569reponame:Revista Fitosinstname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZporhttps://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/1138/1058https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/1138/1059https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/1138/1097Copyright (c) 2022 Revista Fitosinfo:eu-repo/semantics/openAccessRubio, Karina Taciana SantosNascimento, Maria Alice Pereira doMartucci, Maria Elvira Poleti2022-07-15T12:51:23Zoai:ojs.revistafitos.far.fiocruz.br:article/1138Revistahttps://revistafitos.far.fiocruz.br/index.php/revista-fitos/PUBhttp://revistafitos.far.fiocruz.br/index.php/revista-fitos/oairevistafitos@far.fiocruz.br || eugenio.telles@far.fiocruz.br2446-47752446-4775opendoar:2022-07-15T12:51:23Revista Fitos - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.none.fl_str_mv Drug interaction between standardized herbal medicines by the Unified Health System and conventional medicines
Interações medicamentosas entre fitoterápicos padronizados pelo Sistema Único de Saúde e medicamentos convencionais
title Drug interaction between standardized herbal medicines by the Unified Health System and conventional medicines
spellingShingle Drug interaction between standardized herbal medicines by the Unified Health System and conventional medicines
Rubio, Karina Taciana Santos
Phytotherapics
Phytotherapy
Adverse events
Drug interactions
Medicinal plants
Unified Health System
Fitoterápicos
Fitoterapia
Eventos adversos
Interações medicamentosas
Plantas Medicinais
Sistema Único de Saúde
title_short Drug interaction between standardized herbal medicines by the Unified Health System and conventional medicines
title_full Drug interaction between standardized herbal medicines by the Unified Health System and conventional medicines
title_fullStr Drug interaction between standardized herbal medicines by the Unified Health System and conventional medicines
title_full_unstemmed Drug interaction between standardized herbal medicines by the Unified Health System and conventional medicines
title_sort Drug interaction between standardized herbal medicines by the Unified Health System and conventional medicines
author Rubio, Karina Taciana Santos
author_facet Rubio, Karina Taciana Santos
Nascimento, Maria Alice Pereira do
Martucci, Maria Elvira Poleti
author_role author
author2 Nascimento, Maria Alice Pereira do
Martucci, Maria Elvira Poleti
author2_role author
author
dc.contributor.author.fl_str_mv Rubio, Karina Taciana Santos
Nascimento, Maria Alice Pereira do
Martucci, Maria Elvira Poleti
dc.subject.por.fl_str_mv Phytotherapics
Phytotherapy
Adverse events
Drug interactions
Medicinal plants
Unified Health System
Fitoterápicos
Fitoterapia
Eventos adversos
Interações medicamentosas
Plantas Medicinais
Sistema Único de Saúde
topic Phytotherapics
Phytotherapy
Adverse events
Drug interactions
Medicinal plants
Unified Health System
Fitoterápicos
Fitoterapia
Eventos adversos
Interações medicamentosas
Plantas Medicinais
Sistema Único de Saúde
description Medicinal plants and phytotherapics are considered an alternative for the treatment of several diseases. The SUS has 12 phytotherapics standardized in the RENAME: artichoke, mastic, aloe vera, holy cashew, espinheira-santa, devil's claw, guaco, mint, soy isoflavone, plantago, willow and unha-de-gato. The aim of this work was to evaluate the adverse events of these phytotherapics and the possible drug interactions resulting from the use of conventional medicines concomitant with the use of these phytotherapics. The work was carried out through a review of the databases between 1995 and 2020. Medicinal plants and phytotherapics are constituted of chemical compounds, which are mostly responsible for their pharmacological actions. The complexity of these substances increases the possibility of interactions occurring when conventional drugs are used concomitantly. The interactions can be beneficial or unfavorable, since they can increase drug's effect, reduce its effectiveness, result in adverse reactions or not cause changes in the expected effect of the drug. This work emphasizes the importance of considering herbal medicines and phytotherapics with the same importance as synthetic medicines, basing clinical conduct on reliable scientific evidence, recognizing its effectiveness, but also its adverse effects and the possibility of drug interactions making, thus, its use safer and more efficient.
publishDate 2022
dc.date.none.fl_str_mv 2022-06-30
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/1138
10.32712/2446-4775.2022.1138
url https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/1138
identifier_str_mv 10.32712/2446-4775.2022.1138
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/1138/1058
https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/1138/1059
https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/1138/1097
dc.rights.driver.fl_str_mv Copyright (c) 2022 Revista Fitos
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2022 Revista Fitos
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
text/html
text/xml
dc.publisher.none.fl_str_mv Centro de Inovação em Biodiversidade e Saúde - Farmanguinhos/Fiocruz
publisher.none.fl_str_mv Centro de Inovação em Biodiversidade e Saúde - Farmanguinhos/Fiocruz
dc.source.none.fl_str_mv Revista Fitos; Vol. 16 No. 2 (2022); 248-269
Revista Fitos; Vol. 16 Núm. 2 (2022); 248-269
Revista Fitos; v. 16 n. 2 (2022); 248-269
2446-4775
1808-9569
reponame:Revista Fitos
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Revista Fitos
collection Revista Fitos
repository.name.fl_str_mv Revista Fitos - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv revistafitos@far.fiocruz.br || eugenio.telles@far.fiocruz.br
_version_ 1798313475582197760